Clinical trial NCT02033616: Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas
Official title: Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Stage III Ovarian Carcinoma
Stage IV Ovarian Carcinoma
Fallopian Tube Carcinoma
Primary Peritoneal Carcinoma
Lead sponsor: Aivita Biomedical, Inc.
Sponsor class: INDUSTRY
First posted: 2014-01-13
Enrollment: 99
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a double-blind study in which approximately 99 study patients will be randomized in a 2:1 ratio to receive either AVOVA-1 or MC. Patients eligible for randomization and treatment will be those (1) who have undergone debulking surgery, (2) for whom a cell line has been established, (3) who have undergone leukapheresis from which sufficient PMBC were obtained, and (4) have an ECOG performance grade of 0 or 1 (Karnofsky score of 70-100%).

The primary endpoint of this trial is death from any cause with the metric of OS from the date of randomization. PFS will be a secondary endpoint and will be calculated as the time from the date of randomization for treatment until subjective tumor progression or death. Progression will be subjectively defined by the treating physician, and is expected to be based on tumor marker levels (e.g. CA-125) and/or imaging. Secondarily, we will also define PFS and OS from the date of debulking surgery.

Patients will be stratified into (1) no evidence of disease (NED) (no measurable or non-measurable disease per RECIST and normal CA-125 levels) or (2) non-NED (measurable or non-measurable disease per RECIST or elevated CA-125 levels).


Eligibility criteria: Inclusion Criteria:

* ECOG performance status of 0-1 (Karnofsky score of 70-100%)
* Successful establishment of an autologous epithelial ovarian, fallopian tube, or primary peritoneal cancer cell line by AIVITA Biomedical, Inc.
* Patients must previously have been staged as having stage III \[intraperitoneal (IP)\] or Stage IV (distant metastatic) ovarian, fallopian tube, or primary peritoneal cancer, have undergone surgical debulking, and have initiated or completed standard adjuvant chemotherapy, which may include intravenous (IV) and/or IP chemotherapy using standard regimens. Patients will be characterized as being NED or non-NED per physical exam, CT and/or PET scans, and CA-125.
* Have undergone leukapheresis from which sufficient provided PBMC were obtained to produce an investigational treatment.
* Patients with one or a few brain metastases that have been treated with stereotactic radiotherapy consisting of a single dose, such as Gamma Knife or Cyberknife, are allowed to be included in the study, but need wait one week after such treatment.
* Written informed consent for treatment with investigational treatment

Exclusion Criteria:

* Known to have active hepatitis B or C or HIV
* ECOG performance status greater than 1 (Karnofsky score less than 70%).
* Known underlying cardiac disease associated with myocardial dysfunction that requires active medical treatment, or unstable angina related to atherosclerotic cardiovascular disease, or under treatment for arterial or venous peripheral vascular disease
* Diagnosis of any other invasive cancer or other disease process which is considered to be life-threatening within the next five years, and/or taking anti-cancer therapy for cancer other than ovarian (such as continuation of hormonal therapy for prostate or breast cancer diagnosed more than five years earlier).
* Active infection or other active medical condition that could be eminently life-threatening, including active blood clotting or bleeding diathesis.
* Active central nervous system metastases at the time of treatment.
* Known autoimmune disease, immunodeficiency, or disease process that involves the use of immunosuppressive therapy.
* Received another investigational drug within 28 days of the first dose or are planning to receive another investigational drug while receiving this investigational treatment.
* Known hypersensitivity to GM-CSF

Primary outcomes:
measure: Primary Efficacy Endpoint: Overall Survival
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Burbank
country: United States
facility: Disney Family Cancer Center
state: California
city: La Jolla
country: United States
facility: Scripps Health
state: California
city: La Jolla
country: United States
facility: UC San Diego, Moores Cancer Center
state: California
city: Newport Beach
country: United States
facility: Hoag Memorial Hospital Presbyterian
state: California
city: Orange
country: United States
facility: UC Irvine, Chao Family Comprehensive Cancer Center
state: California
city: Aurora
country: United States
facility: University of Colorado Hospital - Cancer Center
state: Colorado
Study officials:
affiliation: Aivita Biomedical, Inc.
name: Robert O Dillman, MD
role: STUDY_CHAIR
References: